Johnson PJ, Berhane S, Walker AJ, et al. - This study was intended to assess the effect of direct-acting antiviral (DAA) agents on liver function in patients with chronic hepatitis C virus infection. Researchers examined a total of 2,394 patients with chronic HCV infection, 1,276 of whom were being treated with DAAs and 1,118 with interferon‐based therapy. Liver function was measured by the ALBI score or grade. Time to the first decompensation according to ALBI grade, and longitudinal changes in ALBI score over time according to SVR were also examined. In this study, 89% of the patients receiving DAAs achieved SVR (Japan=99%, UK=78%). Experience with interferon‐based therapy implies that a long‐term decline in liver function is correlated with a failure to achieve SVR. Those who do achieve SVR can expect long‐term disease improvement and subsequent stabilization of liver function. Patients who get DAAs seem to, in the long term, to follow a comparable course, as indicated by this study.